Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2020

View Archived Issues

In AML, collapse prevents relapse

Notable responses seen in COVID-19 patients with respiratory failure given RLF-100

Daiichi Sankyo describes new SIRT6 activators

G protein-coupled receptor 35 modulators discovered at Precision IBD

Novartis presents NLRP3 inflammasome inhibitors

Merck KGaA discovers dual adenosine A2A/A2B receptor antagonists

Discovery and preclinical evaluation of anticancer agent, PVHD-303

First-in-human data presented for [68Ga]P15-041 radiotracer

Yumanity Therapeutics identifies stearoyl-CoA desaturase 1/5 inhibitors

VBL announces second successful pre-planned interim analysis of the phase III OVAL study

First patient enrolled in phase III InPedILD study of nintedanib

FDA approves Viltepso for the treatment of DMD in patients amenable to exon 53 skipping therapy

First phase I study of ATG-017 approved in Australia

Recombinant SARS-CoV-2 S1-Fc fusion protein shows promise in animal species

Treadwell initiates phase II study of CFI-400945 and durvalumab in TNBC

TREM2 targeting can synergize with checkpoint blockade

Phase I study results support further evaluation of yellow fever monoclonal antibody TY-014

Bio-Path begins dosing in amended stage 2 of phase II prexigebersen study in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...